الفهرس 
AcknowledgmentOnly 14 pages are availabe for public view
 |  | from | 119 |  |  |
| | | from | 119 | | |
Abstract
”Type2 diabetes is a growing global public health problem caused by a combination of pancreatic β-cells dysfunction and the insulin-resistance. Due to its multiple factors of type 2 diabetes pathophysiology, its treatment is varied and based upon multi-therapeutic agents. Dipeptidyl peptidase-4 (DPP-4) inhibitors represent a class of oral glucose lowering therapy that can inhibit DPP-4 enzyme, thus block the breakdown of incretin hormones GLP-1 and GIP in order to increase levels of the active hormones and consequently restoring a lot of the pathophysiological problems of diabetes. Vildagliptin is one of the dipeptidyl peptidase-4 inhibitors that appear to improve glucose-dependent insulin secretion and enhance both insulin sensitivity and the sensitivity of α-cells to glucose. It has been suggested that the enhancement of glucose-dependent insulin secretion as an effect of vildagliptin could indicate the improvement of β-cells function or at least a slowing in the deterioration of β-cells function that characterizes type 2 diabetes; although, there is still a need for more data to confirm this assumption. Thus, this study aimed to explore the role of vildagliptin against the destruction of the pancreatic β-cells whether by inhibiting beta cell apoptosis or decreasing oxidative stress. In the present study : Thirty-two wistar adult male rats weighed about 150 to 200 g from Helwan animal farm, divided into four groups, each group included 8 rats. First group, normal control group, where rats received no treatment. Second group, Normal rats treated with vildagliptin group, rats received vildagliptin (50mg/ kg body weight/ day), oral as emulsion in distilled water for 4 weeks. Third group, diabetic control group, where type 2 diabetes induced by nicotinamide (230 mg/ kg) and streptozotocin (65 mg/ kg). Fourth group, diabetic rats treated with vildagliptin, where type 2 diabetes induced as the third group and received vildagliptin (50mg/ kg body weight/ day), oral as emulsion in distilled water by using feeding tube for 4 weeks.